A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs D-0120 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors InventisBio
- 16 Dec 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2018 Planned End Date changed from 1 Aug 2018 to 10 Oct 2018.